# US 2006/0078944 A1 · Methods and reagents relating to inflammation and apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078944 A1
- Document ID: US20060078944A1
- Status: Published application
- Kind: A1
- Application number: 10/523,328
- Filed: 2003-08-01
- Published: 2006-04-13
- Earliest claimed: 2002-08-01
- Inventors: Jun Kuai; Lih-Ling Lin; Joseph Wooters; Elliott Nickbarg
- Web page: https://patentgrep.com/patent/US20060078944A1

## CPC

- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF-α) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF-κB activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF-α related diseases.

## Claims

### Claim 1

An isolated, purified, or recombinant protein complex comprising:
(i) a tumor necrosis factor alpha (TNF-α) polypeptide or a functional variant thereof;
(ii) a TNF-α receptor (TNFR) polypeptide or a functional variant thereof; and
(iii) at least one polypeptide selected from the group consisting of: NF-κB activating kinase (NAK), RasGAP3, TRCP1, TRCP2 and a functional variant thereof.

### Claim 2 (depends on 1)

The complex of claim 1, wherein the TNFR polypeptide is a TNFR1 or TNFR2 polypeptide.

### Claim 3 (depends on 1)

The complex of claim 1, comprising a TNF-α polypeptide, a TNFR polypeptide and a NAK polypeptide.

### Claim 4 (depends on 1)

The complex of claim 1, comprising a TNF-α polypeptide, a TNFR polypeptide and a RasGAP3 polypeptide.

### Claim 5 (depends on 1)

The complex of claim 1, comprising a TNF-α polypeptide, a TNFR polypeptide and a TRCP1 polypeptide.

### Claim 6 (depends on 1)

The complex of claim 1, comprising a TNF-α polypeptide, a TNFR polypeptide and a TRCP2 polypeptide.

### Claim 7 (depends on 1)

The complex of claim 1, comprising a TNF-α polypeptide, a NAK polypeptide and a TNFR1 polypeptide.

### Claim 8 (depends on 1)

The complex of claim 1, further comprising at least one polypeptide selected from the group consisting of: TRADD, TRAF2, TRAP2 and a functional variant thereof.

### Claim 9 (depends on 8)

The complex of claim 8, comprising a TNF-α polypeptide, a NAK polypeptide, a TNFR1 polypeptide, a TRAF2 polypeptide and a TRADD polypeptide.

### Claim 10 (depends on 8)

The complex of claim 8, comprising a TNF-α polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2-polypeptide, and a TRAP2 polypeptide.

### Claim 11 (depends on 1)

The complex of claim 1, wherein said TNF-α is a fusion protein.

### Claim 12 (depends on 1)

The complex of claim 1, wherein said TNFR is a fusion protein.

### Claim at position 13

13-16. (canceled)

### Claim 17

An isolated, purified, or recombinant protein complex comprising:
(i) a TNF-α receptor (TNFR) polypeptide or a functional variant thereof; and
(ii) at least one polypeptide selected from the group consisting of: NF-κB activating kinase (NAK), RasGAP3, TRCP1, TRCP2 and a functional variant thereof.

### Claim at position 15

18-21. (canceled)

### Claim 22 (depends on 17)

The complex of claim 17, wherein said TNFR polypeptide is a TNFR1 polypeptide or a TNFR2 polypeptide.

### Claim 23 (depends on 17)

The complex of claim 17, further comprising at least one polypeptide selected from the group consisting of: TNF-α, TRADD, TRAF2, and TRAP2.

### Claim 24 (depends on 23)

The complex of claim 23, comprising a TNF-α polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2 polypeptide, and a TRAP2 polypeptide.

### Claim 25 (depends on 17)

The complex of claim 17, wherein said TNFR polypeptide is a fusion protein.

### Claim at position 20

26-32. (canceled)

### Claim 33

A host cell comprising a first nucleic acid, a second nucleic acid and a third nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNF-α polypeptide, wherein the second nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide and wherein the third nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

### Claim 34 (depends on 33)

The host cell of claim 33, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNF-α polypeptide, wherein the second nucleic acid comprises a recombinant nucleic acid encoding a TNFR1 polypeptide and wherein the third nucleic acid comprises a recombinant nucleic acid encoding a NAK polypeptide.

### Claim 35

A host cell comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR, and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

### Claim 36 (depends on 35)

The host cell of claim 35, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR1 polypeptide and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a NAK polypeptide.

### Claim 37

An assay for identifying a test compound which inhibits or potentiates the stability of a complex, comprising:
(a) forming a reaction mixture including:
(i) a TNF-α polypeptide;
(ii) a TNFR polypeptide;
(iii) at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; and
(iv) a test compound; and
(b) detecting the presence of TNF-α or TNFR in the complex;
wherein a change in the presence of TNF-α or TNFR in the complex in the presence of the test compound, relative to the presence of TNF-α or TNFR in the complex in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.

### Claim 38

(canceled)

### Claim 39

An assay for identifying a test compound which inhibits or potentiates the stability of a complex, comprising:
(a) forming a reaction mixture including:
(i) a TNFR polypeptide;
(ii) at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; and
(iii) a test compound; and
(b) detecting the association between the TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
wherein a change in the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the presence of the test compound, relative to the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.

### Claim at position 28

40-43. (canceled)

### Claim 44

A method for modulating, in a cell, a protein complex comprising at least a first protein and a second protein, wherein said first protein is TNFR, and wherein said second protein is selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, said method comprising: administering to said cell a compound capable of modulating said protein complex.

### Claim 45 (depends on 44)

The method of claim 44, wherein the protein complex further comprises TNF-α.

### Claim 46

A method of producing a functional complex comprising:
(i) transfecting a cell with a polynucleotide encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
(ii) contacting said cell with a TNF-α polypeptide;
(iii) thereby forming a complex.

### Claim 47 (depends on 46)

The method of claim 46, further comprising a TNFR polypeptide.

### Claim 48

A method for treating a TNF-α-related disorder, by administering an effective amount of a compound that inhibits the interaction of TNF-α or TNFR with a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

### Claim 49 (depends on 48)

The method of claim 48, wherein said compound is selected from the group consisting of: a small molecule, an antibody, and a peptide.

### Claim 50

A method of identifying a test compound that is a candidate modulator of inflammation or apoptosis, the method comprising:
(i) forming a mixture comprising a TRCP1 polypeptide or a variant polypeptide thereof, and a test compound; and
(ii) measuring the interaction between the TRCP1 polypeptide or the variant and the test compound;
wherein a test compound that interacts with the TRCP1 polypeptide or functional variant is a candidate modulator of inflammation or apoptosis.

### Claim 51 (depends on 50)

The method of claim 50, wherein (i) comprises forming the mixture in vitro.

### Claim 52 (depends on 50)

The method of claim 50, wherein (i) comprises contacting a cell expressing a TRCP1 polypeptide or a variant thereof, with the test compound.

### Claim 53

A method of identifying a test compound that is a candidate modulator of inflammation or apoptosis, the method comprising:
(i) forming a mixture comprising a TRCP2 polypeptide or a variant polypeptide thereof, and a test compound; and
(ii) measuring the interaction between the TRCP2 polypeptide or the variant and the test compound;
wherein a test compound that interacts with the TRCP2 polypeptide or functional variant is a candidate modulator of inflammation or apoptosis.

### Claim 54 (depends on 53)

The method of claim 53, wherein (i) comprises forming the mixture in vitro.

### Claim 55 (depends on 53)

The method of claim 53, wherein (i) comprises contacting a cell expressing a TRCP2 polypeptide or a variant thereof, with the test compound.

### Claim 56

A method of treating a TNF-α-related disease which includes an inflammatory or apoptotic component, by administering an effective amount of a therapeutic composition that modulates TRCP1 or TRCP2.

### Claim 57

(canceled)
